Value of cytokeratin-19, Hector Battifora mesothelial-1 and galectin-3 immunostaining in the diagnosis of thyroid neoplasms

Abstract BACKGROUND: Diagnosis of types and aggressiveness of thyroid cancers is difficult. The "gold standard" in diagnosis is using routine hematoxylin and eosin staining. Several markers have been investigated for differentiating them among which cytokeratin-19 (CK-19), Hector Battifora mesothelial cell (HBME-1), and galectin-3 are found to be most commonly used. Most studies have evaluated the single expression of markers in various thyroid lesions. AIMS AND OBJECTIVES: To know the value of immunohistochemical expression of CK-19, HBME-1, and galectin-3 in diagnosing thyroid neoplasms. To study the expression and compare the results of HBME-1, CK-19, and galectin-3 immunohistochemical markers in histopathologically diagnosed malignant lesions and nonmalignant lesions and demonstrate their usefulness in differentiating them. MATERIALS AND METHODS: A prospective study was carried out on thyroidectomy specimens sent in 10% buffered formalin to Department of Pathology, SVIMS, Tirupati, from May 2013 to August 2014. Sensitivity and specificity for each marker and their combination in diagnosis were calculated. RESULTS: Among 120 cases, nonmalignant lesions were 70 (58.33%) and malignant lesions 50 (41.67%). Among nonmalignant lesions, 65 (93%) were adenomatous goiter and 5 (7%) were follicular adenomas. In malignant lesions, 48 (96%) were papillary carcinoma and 1 (2%) each of follicular carcinoma and anaplastic carcinoma. Among papillary carcinomas, classical were 26 (54.16%) followed by 17 follicular variant (35.41%). Galectin-3 had highest sensitivity of 90% and HBME-1 had highest specificity of 97.14%. CONCLUSIONS: Panel of HBME-1+ galectin-3 or CK-19, HBME-1, and galectin-3 increase the accuracy of diagnosis in histopathologically difficult cases.

[1]  V. Satyanarayana,et al.  Profile Of Thyroid Neoplasms With Special Focus On Interesting Cases: A Hospital Based 12 Year Longitudinal Study , 2013 .

[2]  J. Gardovskis,et al.  Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules. , 2012, Medicina.

[3]  Chang-Sheng Li,et al.  Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China , 2011, Diagnostic pathology.

[4]  A. Faur,et al.  THE VALUE OF CK19, KI-67 AND P53 EXPRESSION IN THE DIAGNOSIS OF THYROID FOLLICULAR NEOPLASMS , 2011 .

[5]  S. Seçkın,et al.  Expression of CK-19, cErbB2, galectin-3, and p53 in papillary thyroid carcinomas , 2010, Turkish Journal of Medical Sciences.

[6]  S. Kwak,et al.  Diagnostic Value of Galectin-3, HBME-1, Cytokeratin 19, High Molecular Weight Cytokeratin, Cyclin D1 and p27kip1 in the Differential Diagnosis of Thyroid Nodules , 2007, Journal of Korean medical science.

[7]  S. Mukhopadhyay,et al.  Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining , 2006, Modern Pathology.

[8]  Yao-Tseng Chen,et al.  Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. , 2006, American journal of clinical pathology.

[9]  K. Young,et al.  Usefulness of Galectin-3, Cytokeratin 19, p53, and Ki-67 for the Differential Diagnosis of Thyroid Tumors , 2006 .

[10]  K. Metze,et al.  Usefulness of HBME‐1, cytokeratin 19 and galectin‐3 immunostaining in the diagnosis of thyroid malignancy , 2005, Histopathology.

[11]  M. Papotti,et al.  Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential , 2005, Modern Pathology.

[12]  H. Nagaraja,et al.  Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors , 2005, Modern Pathology.

[13]  L. Truong,et al.  Cytokeratin 19 immunolocalization in cell block preparation of thyroid aspirates. An adjunct to fine-needle aspiration diagnosis of papillary thyroid carcinoma. , 2003, Archives of pathology & laboratory medicine.

[14]  M. Beesley,et al.  Cytokeratin 19 and galectin‐3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules , 2002, Histopathology.

[15]  C. Cheung,et al.  Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma , 2001, Modern Pathology.

[16]  L. Grimelius,et al.  Cytokeratin 19 expression in papillary thyroid carcinoma , 1999 .

[17]  T. Jo,et al.  Thyroid cancers in Ibadan, Nigeria. , 1995 .

[18]  J. Ogunbiyi,et al.  Thyroid cancers in Ibadan, Nigeria. , 1995, East African medical journal.

[19]  A. R. Khan,et al.  Pattern of cancer at Asir Central Hospital, Abha, Saudi Arabia. , 1991, Annals of Saudi medicine.

[20]  G. Ejeckam,et al.  Histological pattern of thyroid diseases in Enugu, Nigeria. , 1983, East African Medical Journal.

[21]  W. Gitau An analysis of thyroid diseases seen at Kenyatta National Hospital. , 1975, East African medical journal.

[22]  B. M. Black,et al.  Occult papillary carcinoma of the thyroid gland: a study of 140 cases observed in a 30-year period. , 1960, The Journal of clinical endocrinology and metabolism.